Pinned Brian Lord @briantlord Mar 17 🚨 New preprint from SEMA Lab! 🚨 We applied our tFUS meditation enhancement proto...
SEMA Lab posted a new preprint and related social commentary about using transcranial focused ultrasound (tFUS) paired with a two-week meditation protocol to alter Default Mode Network (DMN) connectivity and promote “equanimity.” This is academic, early-stage research without explicit commercial claims, regulatory milestones, or named productization.
Linked assets
Related tickers represent category-adjacent neuromodulation exposure rather than direct read-throughs from the preprint: BWAY (indirect exposure to neuromodulation category), ECOR (small-cap name that may trade with the broader brain-stimulation narrative), and NPCE (implantable neuromodulation; possible thematic halo effects only).
Category-adjacent exposure to neuromodulation; no direct link to tFUS in the preprint.
Category-adjacent neuromodulation exposure; relationship to tFUS is indirect.
Small-cap neuromodulation name that could be sentimentally affected by brain-stimulation news but lacks mechanistic linkage to this study.
Small-cap neuromodulation name that may trade with the broader ‘brain stimulation’ narrative, but not mechanistically linked.
Implantable neuromodulation company; possible thematic halo effects only, no direct read-through from meditation/tFUS preprint.
Implantable neuromodulation; could see thematic halo effects, but no direct read-through from a meditation/tFUS preprint.
Source proof
Source proof: Strong source proof | 2 extracted claims | 3 directional assets | 1 supporting author | headline-like title review
Sources include a Biological Psychiatry paper and an academic preprint from SEMA Lab (authored/highlighted by Brian Lord @briantlord) describing placebo-controlled tFUS paired with meditation and reporting DMN connectivity changes. The material is conceptual/experimental and does not disclose company partnerships, commercialization plans, or regulatory timelines.
SEMA Lab author Brian Lord highlights a newly published Biological Psychiatry paper describing a theoretical framework for combining mindfulness interventions with non-invasive brain stimulation to “enhance equanimity.” This is early-stage, conceptual academic content with no explicit commercial product, timeline, or listed public company tie-ins.
Academic preprint describing a placebo-controlled study applying transcranial focused ultrasound (tFUS) to the posterior cingulate cortex (PCC) during a two-week meditation training course, reporting changes in Default Mode Network (DMN) connectivity/desegregation. No company, commercialization path, FDA/regulatory milestone, revenue impact, or named products are provided, so near-term investability is low.
The content is a social-media reply asking PropheticAI (and a user) whether technical information will be published. It contains no market, macro, company fundamentals, product launch, or financial guidance details that would support a tradable thesis.
A social post expressing concern about whether PropheticAI is doing proper safety testing; signals reputational/regulatory risk sensitivity around AI/health/neurotech, but contains no concrete claims, data, timelines, product details, or market-moving information.
Supporting authors
Author count: 1 (SEMA Lab / Brian Lord). Social-media replies referenced technical-publication and safety-testing questions but do not add commercial or investable detail.
Unlock full thesis monitoring
Implication for investors: not directly tradable. Use only as marginal supportive evidence for a long-duration thematic basket exposure to neuromodulation rather than as a catalyst for single-stock trades.